Patents by Inventor Johnathan Lancaster

Johnathan Lancaster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9528982
    Abstract: Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: December 27, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Johnathan Lancaster, Douglas Marchion, Dung-Tsa Chen
  • Patent number: 9063143
    Abstract: The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: June 23, 2015
    Assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Johnathan Lancaster, Douglas C. Marchion, Dung-Tsa Chen
  • Publication number: 20140017703
    Abstract: Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status.
    Type: Application
    Filed: August 26, 2013
    Publication date: January 16, 2014
    Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Johnathan Lancaster, Douglas Marchion, Dung-Tsa Chen
  • Patent number: 7655479
    Abstract: Luminescent semiconductor quantum dots (QDs) conjugated with biomolecules to serve as sensitive probes for early detection of the cancer cells, specifically for ovarian cancer and lung cancer, which represents the most lethal malignancies. The luminescence characterization of the bin-conjugated QDs with cancer specific antigens using linkage molecules. Photo-enhancement is measured at various laser density power, temperatures and laser wavelengths.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: February 2, 2010
    Assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc., The Regents of the University of California
    Inventors: Tatyana A. Zhukov, Sergei Ostapenko, Rebecca Sutphen, Johnathan Lancaster, Thomas A. Sellers, Jin Z. Zhang
  • Publication number: 20070172844
    Abstract: The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer.
    Type: Application
    Filed: September 28, 2006
    Publication date: July 26, 2007
    Applicants: University of South Florida, Duke University
    Inventors: Johnathan Lancaster, Joseph Nevins
  • Publication number: 20060003465
    Abstract: Luminescent semiconductor quantum dots (QDs) conjugated with biomolecules to serve as sensitive probes for early detection of the cancer cells, specifically for ovarian cancer and lung cancer, which represents the most lethal malignancies. The luminescence characterization of the bin-conjugated QDs with cancer specific antigens using linkage molecules. Photo-enhancement is measured at various laser density power, temperatures and laser wavelengths.
    Type: Application
    Filed: June 30, 2005
    Publication date: January 5, 2006
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Tatyana Zhukov, Sergei Ostapenko, Rebecca Sutphen, Johnathan Lancaster, Thomas Sellers, Jin Zhang